Syngeneic tumor models in animals
Immunotherapy has shown remarkable anticancer activity, with several immunotherapeutic modalities already approved by the Food and Drug Administration (FDA) for treating cancer patients (Papaioannou NE, et al. Ann Transl Med. 2016; 4 (14): 261). Nevertheless, current immunotherapies only benefit 20–30% of patients in susceptible tumor types such as melanoma, non-small cell lung cancer and renal cell carcinoma.
In order to investigate the antitumor activity of test compounds in a normal and complete immune system, syngeneic tumor models in immuno-competent mice are therefore proposed. Syngeneic mouse models have the important advantage of allowing analyses to be carried out in animals with normal immune function. Because the immune system plays an important role in the development and progression of cancer, models that can be used in immunocompetent mice are essential for analysis of cancer progression and evaluation of therapeutics for cancer treatment.
For this purpose, Cellvax has developed a number of syngeneic tumor models.